Is this message not displayed correctly?
Please click here for the online version.
|
|
Dear Sir or Madam,
What is required to transfer life science into healthcare innovations? Laboratory space, qualified employees, and money! None of these are easy to find.
In our cluster HealthCapital Berlin-Brandenburg, the cluster management will help you to navigate the network and to find talent, laboratories, and financing.
In this issue of our newsletter, we present solutions, initiatives, and success stories in the areas of real estate, skilled labor, and financing.
Get to know HYBRICK, a company which develops modern laboratory and production areas for the life science industry. And the story of Berlin-based radiopharmaceutical company Ariceum Therapeutics, which successfully completed a second round of financing in April with around €23 million, shows that the capital region is a good place to find partners and investors.
In our focus article “Education and training” we inform you about the various activities in Berlin and Brandenburg that are available for the qualification of skilled workers
We look forward to many upcoming networking opportunities. Visit the World Health Summit in Berlin (October 15-17) or meet us at BIO Europe (November 6-8) or Medica (November 13-16)!
Your
Dr. Kai Uwe Bindseil
Berlin Partner for Business and Technology |
|
Special Topic | Well-trained professionals in the healthcare industry – The metropolitan region has a lot to offer Where can companies and research institutions find freshly trained specialists for their requirements, how and where can their own workforce be trained and how can schoolchildren be inspired for the industry? We present some initiatives and give an overview where you can get further information. |
|
|
In portrait | Ariceum
Targeting and eliminating cancer cells Berlin-based Ariceum Therapeutics develops radiopharmaceuticals to diagnose and treat difficult-to-treat cancers. Founded in 2021, Ariceum already has numerous financially strong partners and investors on board and expects the first product to be approved in 2028. |
|
|
In portrait | HYBRICK – Modern laboratory and production space for the life science industry Berlin-Brandenburg is one of the world’s leading life science locations, resulting in high demand for real estate within the industry here. The demands on this real estate have increased, especially in terms of the flexibility of the premises. Therefore, HYBRICK offers contemporary laboratory and production facilities that meet these and other requirements. A first new building is currently being developed at the heart of the south of Berlin. |
|
|
The tip from our relocation experts The decision to relocate to a new city which provides the suitable environment to grow a business is not easy. To make the decision easier for you, we’ve gathered the key facts that you need to decide for Berlin: |
|
|
- Lots of startups in one place are an indicator for a suitable breeding ground. In Berlin every year, more than 500 startups are founded. Read here about starting up in Berlin.
- It is easy to get financing in Berlin because much money is flowing into startups. For example, the range of programs offered by Investitionsbank Berlin covers the founding and growth phases of startups with grants, loans and equity investments. You will find a comprehensive overview of funding possibilities here: Backing in Berlin.
- Berlin offers a very good startup infrastructure: The Startup Heatmap Europe 2022 puts Berlin in first place, ahead of London and Barcelona.
- Berlin is an international talent pool and one of the most attractive cities for young professionals.
You can always contact our relocation managers for more details and further questions.
So what are you waiting for? We are looking forward to getting in touch and assisting you in setting up your business in Berlin.
Susan Kaffenberger
Berlin Partner for Business and Technology
Biotech | Pharma 📧 |
|
|
|
The MedTech Conference
October 9-11, 2023 Anaheim, California, USA Read more |
|
BIO Japan 2023
October 11-13, 2023 | Japan
|
World Health Summit
2023
October 15-17, 2023 | Berlin, Germany Read more
|
|
|
12th International
Biotech Innovation Days
October 17-19, 2023 | Senftenberg, Germany
|
|
|
BIO Europe 2023
November 6-8, 2023 | Munich, Germany
|
|
|
Falling Walls Science
Summit 2023
November, 7-9, 2023 | Berlin, Germany
|
|
|
Future Medicine Science
Match 2023
November 9, 2023 | Berlin, Germany
|
|
|
MEDICA 2023
November, 13-16, 2023 | Düsseldorf, Germany
Read more
|
|
|
RegMed Forum 2023 | ATMPs – Thinking Big, Inclusive and Beyond Rare Disease!
November 23, 2023 | Berlin, Germany Read more |
|
3rd AM Medical Days Berlin 2023
December 11-12, 2023 | Berlin, Germany Read more |
|
For more events in the life science region Berlin-Brandenburg click here. |
|
OMEICOS Therapeutics receives 2.5 million Euros in grant funding supporting OMT-28’s development in mitochondrial diseases through a phase 2a clinical study
OMEICOS, a biopharmaceutical company developing first-in-class small molecule therapeutics based on the profound understanding of omega-3 fatty acid metabolism and physiology, announced today that the Company has received a significant grant by the German Federal Ministry of Education and Research (“BMBF”) strongly supporting the development of OMEICOS’ lead product candidate OMT-28*. Read more |
|
Using an app to combat skin conditions: Nia Health receives millions in funding
The Berlin-based health tech start-up Nia Health receives 3.5 million euros in a seed financing round. The company originates from the Charité Universitätsmedizin Berlin and operates leading dermatology apps, including “Nia,” the most widely downloaded app for people with atopic dermatitis. Read more |
|
MyoPax receives FDA orphan drug designation
MyoPax has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for its regenerative cell therapy in Exstrophy-Epispadias Complex (EEC). MyoPax aims to repair the congenital muscle defect associated with EEC using its cutting-edge highly regenerative muscle stem cell product. Read more |
|
TimeTeller reads your inner clock: Tenth spin-off of the BIH Digital Health Accelerator pinpoints the best time to exercise, sleep and take medicine
An interdisciplinary team led by Prof. Angela Relógio, a scientist at Charité’s Molecular Cancer Research Center (MKFZ) and Institute for Theoretical Biology and the MSH Medical School Hamburg, has developed a non-invasive method for profiling a person’s unique circadian rhythm. Starting with a simple saliva sample, the team of experts can create a detailed description of the body’s internal clock by combining molecular analysis and computational modeling. The goal is to provide personalized recommendations for adjusting lifestyle factors or treatment timing to the circadian rhythm. Read more |
|
3Z and biotx.ai forge partnership to advance ADHD drug development using AI modelling Reykjavik-based drug discovery company, 3Z, and Germany/US-based causal AI firm, biotx.ai, have joined forces in a strategic partnership aimed at revolutionizing ADHD drug development. By leveraging advanced AI modelling techniques, the collaboration seeks to bridge the gap between animal studies and human clinical trials, enabling a more efficient and accurate translation of promising therapeutics. |
ReWalk Robotics announces closing of acquisition of AlterG ReWalk Robotics, a leading provider of innovative technologies that enable mobility and wellness in rehabilitation and daily life for individuals with neurological conditions, today announced closing of the acquisition of AlterG , a leading innovator and leading provider of Anti-Gravity systems for use in physical and neurological rehabilitation. |
|
|
Max Delbrück Center scientists contribute to study that created the most comprehensive cell atlas of the human heart which include the cells from which the heartbeat originates British and German scientists created the most comprehensive cell atlas of the human heart. As reported in the journal “Nature”, it is the first to include the cells from which the heartbeat originates. Among other things, this data will provide a reference for studies on cardiac arrhythmias.
|
|
|
Researchers at the Max Planck Institute of Colloids and Interfaces (MPICI) have designed a carbohydrate sequence capable of folding into a stable secondary structure Researchers at the Max Planck Institute of Colloids and Interfaces (MPICI) have designed a carbohydrate sequence capable of folding into a stable secondary structure. Until now, such self-folding biopolymers had only been developed for DNA and proteins, and sugars were previously considered too flexible to assume a stable conformation. Folded carbohydrates could open up completely new perspectives in biomedicine and materials science. |
|
|
Scientists of the DIfE have revealed expression patterns of key receptors in the mouse hypothalamus There is growing evidence that peptide hormones from the gut have far-reaching effects on the whole organism. By binding to corresponding receptors in the brain, they can modulate food intake and alter metabolic parameters. However, the role of these peptide receptors in critical developmental phases has not yet been thoroughly investigated. Scientists of the junior research group Neurocircuit Development and Function at DIfE have investigated this question and studied the expression patterns of key receptors in the mouse hypothalamus. Their newly obtained findings have been published in the journal PLOS One. |
|
|
Brandenburg University of Technology Cottbus-Senftenberg have discovered a novel treatment approach for soft tissue tumors
Researchers from the Leibniz Institute on Aging in Jena and the Brandenburg University of Technology Cottbus-Senftenberg have discovered a novel treatment approach for soft tissue tumors, which are frequently occurring in children and are often malignant. Read more |
|
Scientists from the Max Delbrück Center discovered a potential new biomarker for Alzheimer’s
The Arl8b protein provides new insights into the mechanisms underlying Alzheimer’s disease. It also has the potential to function as a diagnostic marker. The scientists behind this discovery, a team led by Erich Wanker from the Max Delbrück Center, have published their findings in “Genome Medicine”. Read more |
|
Scientists from BIH and Max Delbrück Center discover that T cells of the immune system are especially sensitive to genetic disturbances within their mitochondrial power plants
Some T cells of the immune system are especially sensitive to genetic disturbances within their mitochondrial power plants. Scientists from BIH and Max Delbrück Center have now published their findings in the journal “Nature Genetics”. Read more |
|
Ten million euros for improved treatment of multiple sclerosis - Charité heads public-private partnership aimed at developing a diagnostic platform
Multiple sclerosis (MS) can take many different forms, which is why it is sometimes called “the disease of a thousand faces.” MS is also complex and difficult to treat. Now, an international consortium headed by Charité – Universitätsmedizin Berlin aims to change that. The partners plan to develop an AI-supported online platform that can predict the course of MS on an individual basis to make it easier to identify the best treatment for specific patients. The project, titled “Clinical impact through AI-assisted MS care” (CLAIMS), will be receiving nearly 10 million euros in funding for four years as part of the EU’s Innovative Health Initiative. Read more |
|
Comprehensive cancer medicine: Charité partners with oncology center in Seoul
Charité – Universitätsmedizin Berlin and the Samsung Comprehensive Cancer Center in Seoul have signed a memorandum of understanding. As part of this partnership, the Charité Comprehensive Cancer Center (CCCC) and the Samsung Comprehensive Cancer Center (SCCC) will collaborate intensively and share their knowledge in cancer care, therapies, and oncological research, with the aim of promoting and enhancing cancer medicine. Read more |
|
TechnologyAndCooperationOffers
|
|
|
Human TCR constructs for adoptive cell therapy of cancer and infectious disease
Read more |
|
The CXCR3alt-CXCL11 chemokine system for diagnostic and therapeutic use in solid cancer
Read more |
|
TCR/CD3-specific CAR NK-92 cells for purification of TCR-modified T cell products
Read more |
|
For more news from the cluster healthcare industries click here. |
|
EDITOR | IMPRINT
This newsletter is operated by the Cluster Management healthcare industries Berlin-Brandenburg HealthCapital.
Berlin Partner for Business and Technology GmbH
Fasanenstrasse 85 | 10623 Berlin | Germany
Phone +49 30 46302-463
Email: info (at) healthcapital.de
Commercial Registry Entry
Entered in the commercial registry of the Charlottenburg District Court,
Registration number: HRB 13072 B
VAT ID: DE 136629780
CEO: Dr. Stefan Franzke
Chairman of the Supervisory Board: Carsten Jung
© 2023 Berlin Partner for Business and Technology GmbH |
|
The newsletter of the Cluster healthcare industries Berlin-Brandenburg is a project of Berlin Partner for Business and Technology.
|
|
|
You have been forwarded this newsletter and would like to subscribe?
Please click here.You want to unsubscribe from the newsletter (to: unknown@noemail.com)? Please click here.
|
|
|
|
|
